Race Oncology 发现其候选药物 （E，E）-双桑曲酮通过阻断拓扑异构酶 II 杀死癌细胞，帮助其开发。 Race Oncology finds its drug candidate (E,E)-bisantrene kills cancer cells by blocking topoisomerase II, aiding its development.

Race Oncology 已确定其主要候选药物 （E，E）-双桑特烯主要通过抑制拓扑异构酶 II、破坏 DNA 复制和触发癌细胞死亡来对抗癌症。 Race Oncology has identified that its lead drug candidate, (E,E)-bisantrene, fights cancer primarily by inhibiting topoisomerase II, disrupting DNA replication and triggering cancer cell death. 该发现基于2025年10月1日公布的新研究, 强化了药物的发展途径, 支持其抗抗性癌症的潜力。 The discovery, based on new research published October 1, 2025, strengthens the drug’s development pathway and supports its potential against resistant cancers. 研究结果加强了临床规划和剂量战略,因为药物通过临床前期和早期临床评估不断进步。 The finding enhances clinical planning and dosing strategies as the drug advances through preclinical and early clinical evaluation. 该公司在ASX和OTC上市,在澳大利亚各地和其他地方的采矿、能源和生物技术部门进行更广泛的更新的同时,继续形成势头。 The company, listed on the ASX and OTC, continues to build momentum amid broader updates in mining, energy, and biotech sectors across Australia and beyond.